Study identifier:ACE-CL-110
ClinicalTrials.gov identifier:NCT03328273
EudraCT identifier:2016-003737-15
CTIS identifier:N/A
A Phase 1 Proof-of-Concept Study Investigating AZD6738 monotherapy and Acalabrutinib in Combination with AZD6738 (ATR inhibitor) in Subjects with Relapsed or Refractory High-risk Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Phase 1
No
Ceralasertib, Acalabrutinib
All
11
Interventional
18 Years - 130 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jun 2024 by AcertaPharma
AcertaPharma
-
No locations available
Arms | Assigned Interventions |
---|---|
Other: Arm A Part 1 and 2 DISCONTINUED (ceralasertib monotherapy) | Drug: Ceralasertib An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR). Other Name: AZD6738 |
Experimental: Arm B Part 1 and 2 ceralasertib + acalabrutinib in combination | Drug: Ceralasertib An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR). Other Name: AZD6738 Drug: Acalabrutinib An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor. Other Name: ACP196 |